| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2016 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 12,000 | $33.39 | $400,640.00 | -5.4% | |
| Feb 1, 2016 | PAHC Phibro Animal Health Corp | Miller Larry Lee | President | Sell | 60,000 | $33.58 | $2,014,800.00 | -100% | |
| Feb 1, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Tarriff Scott | President And CEO | Sell | 18,360 | $68.08 | $1,249,974.34 | -0.3% | |
| Feb 1, 2016 | LFCR Lifecore Biomedical, Inc. \de\ | Frank Fred | Director | Sell | 5,627 | $12.00 | $67,524.00 | -12.2% | |
| Feb 1, 2016 | AMRN Amarin Corp Plc\uk | Thero John F | President And CEO | Buy | 25,000 | $1.37 | $34,250.00 | +3.9% | |
| Feb 1, 2016 | SNY Sanofi | Sanofi | 10% Owner | Buy | 205,030 | $69.75 | $14,300,842.50 | +2.0% | |
| Feb 1, 2016 | LLY Eli Lilly & Co | Tai Jackson P | Director | Buy | 3,170 | $78.62 | $249,225.40 | +8.7% | |
| Jan 29, 2016 | PCRX Pacira Biosciences, Inc. | Braunstein Scott | SVP, Strategy &Corp. Dev. | Buy | 2,000 | $58.92 | $117,840.00 | New | |
| Jan 29, 2016 | LLY Eli Lilly & Co | Zulueta Alfonso G | SVP&Pres., Emerging Markets | Sell | 5,000 | $78.75 | $393,750.00 | -8.1% | |
| Jan 29, 2016 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 39,944 | $32.10 | $1,282,159.84 | -18.0% | |
| Jan 29, 2016 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 39,944 | $32.10 | $1,282,159.84 | -18.0% | |
| Jan 28, 2016 | BCRX Biocryst Pharmaceuticals Inc | Baker Bros. Advisors LP59 | 10% Owner | Buy | 88,345 | $6.95 | $613,985.73 | +0.4% | |
| Jan 27, 2016 | PCRX Pacira Biosciences, Inc. | Jones James B | SVP &Chief Medical Officer | Buy | 500 | $62.50 | $31,250.00 | +50.0% | |
| Jan 27, 2016 | ESPR Esperion Therapeutics, Inc. | Mayleben Timothy M | President &CEO | Buy | 3,600 | $15.88 | $57,168.00 | +11.6% | |
| Jan 26, 2016 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Chief Operating Officer | Sell | 12,923 | $32.13 | $415,215.99 | -100% | |
| Jan 26, 2016 | PAHC Phibro Animal Health Corp | Welch Daniel A | Sr VP, Human Resources | Sell | 3,000 | $32.05 | $96,150.00 | -100% | |
| Jan 22, 2016 | BCRX Biocryst Pharmaceuticals Inc | Baker Bros. Advisors LP59 | 10% Owner | Buy | 106,800 | $7.28 | $777,757.44 | +0.4% | |
| Jan 22, 2016 | PAHC Phibro Animal Health Corp | Miller Larry Lee | President | Sell | 51,225 | $30.07 | $1,540,415.03 | -100% | |
| Jan 20, 2016 | AYTU Aytu Biopharma, Inc | Disbrow Joshua R.57 | Chief Executive Officer | Buy | 153,846 | $0.65 | $99,999.90 | New | |
| Jan 20, 2016 | AYTU Aytu Biopharma, Inc | Disbrow Jarrett | Chief Operating Officer | Buy | 153,846 | $0.65 | $99,999.90 | New | |
| Jan 20, 2016 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Chief Operating Officer | Sell | 8,000 | $29.27 | $234,160.00 | -100% | |
| Jan 20, 2016 | CANN Trees Corp (colorado) | Frichtel Robert Lawrence | CEO | Buy | 2,000 | $0.48 | $950.00 | - | |
| Jan 20, 2016 | BCRX Biocryst Pharmaceuticals Inc | Baker Bros. Advisors LP59 | 10% Owner | Buy | 344,895 | $7.28 | $2,510,143.35 | +0.6% | |
| Jan 15, 2016 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 15,000 | $63.84 | $957,591.84 | -43.8% | |
| Jan 15, 2016 | ESPR Esperion Therapeutics, Inc. | Mayleben Timothy M | President &CEO | Buy | 7,200 | $14.08 | $101,376.00 | +30.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.